 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Between 35.8 and 60% in animal studies. |
| Metabolism | Liver |
| Elimination half-life | 1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively. |
| Excretion | 7.0% urine 87.2% faeces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C42H59N3O10 |
| Molar mass | 765.945 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 211 to 213 °C (412 to 415 °F) |
| |
| |
  (what is this?) (verify) | |
Cethromycin, trade name Restanza (initially known as ABT-773 [1] [2] ) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) [1] [3] [4] [5] and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. [6] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
On October 1, 2008, Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia. [7]
On December 3, 2008, Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA. [8]
In June 2009, an FDA Anti-Infective Drugs Advisory Committee review found insufficient evidence for cethromycin efficacy in treatment of community acquired pneumonia, as the Phase 3 clinical trial followed standards that were updated after the clinical trial but three months prior to review. The committee did, however, find the drug safe to use. [9]